Pharmacy Times

DECEMBER 29, 2022

From newsworthy moments to groundbreaking research, these were the most-read articles on Pharmacy Times in 2022.

151

151

Drug Topics

DECEMBER 29, 2022

The American Diabetes Association has updated their Standards of Care, which includes new hypertension guidelines, medication guidance, and emphasis on weight loss.

98

98

Fierce Pharma

DECEMBER 29, 2022

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report. aarmstrong. Thu, 12/29/2022 - 14:42.

FDA 129

FDA 129

pharmaphorum

DECEMBER 29, 2022

The turbulence of the last three years can make it seem as though pharma manufacturers have been operating in an atmosphere of non-stop crisis. COVID-19 erupted, mutated, and was supplemented by the challenges of monkeypox and the need to catch up with major treatment and immunisation backlogs accumulated during the pandemic. At the same time, the industry must address the long-term difficulty of providing essential medicines and health services to the high percentage of global population that c

Vaccines 108

Vaccines 108

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Store News

DECEMBER 29, 2022

The second panel at Drug Store New’s 24th annual Industry Issues Summit explored how retailers and pharmacy technology companies are responding to customers’ and patients’ needs.

105

105

STAT

DECEMBER 29, 2022

The very term “chronic disease” might imply that little changes — or improves — over time. But there is a lot percolating on the chronic disease front, from the mysterious (long Covid) to well-known problems. For the millions of people in the United States who have one or more chronic conditions, a small scientific stir can lead to a huge impact.

103

103

STAT

DECEMBER 29, 2022

The 22nd year of the 21st century, like most years before it, had its share of turbulence, offering opinion/perspective authors a wealth of topics to write about. STAT published nearly 500 First Opinion essays in 2022, written by more than 700 authors from the biopharmaceutical industry, health care, academia, government, and private life in the United States and beyond.

Medical Records 101

Medical Records 101

Board Vitals - Pharmacist

DECEMBER 29, 2022

We dug through Instagram and asked for nominations to come up with a list of Instagram doctors you may not know about but absolutely must follow immediately. Instagram is a great place to catch up on the latest trends, find motivation, and learn about people and things you may not have known before. Physician accounts on Instagram are a great way to get some interesting insights and knowledge.

Hospitals 98

Hospitals Medical Schools Patient Care 98

STAT

DECEMBER 29, 2022

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients and taxpayers, according to a congressional investigation that cites thousands of pages of internal Biogen documents. More than a year before Aduhelm’s June 2021 approval, Biogen surveyed insurance companies and doctors about how much the Alzheimer’s treatment should cost.

Insurance 98

Insurance Documentation FDA 98

DiversifyRx

DECEMBER 29, 2022

Explore our Top 2022 recommendations for Optimizing Your PBM Revenue and Stabilizing Your Pharmacy Profits. Last week we shared our Top 2022 Pharmacy Blog Post for Non-PBM Revenue , which covers our second Pharmacy Profit Pillar Non-PBM Revenue. This week we will recap the most popular blogs from 2022 that focus on PBM Optimization , our third Pharmacy Profit Pillar.

Patient Care 98

Patient Care 98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

DECEMBER 29, 2022

Congressional investigators sorted through more than 500,000 pages of documents from the Food and Drug Administration and Biogen to chronicle how a controversial Alzheimer’s disease drug was approved, and how it went from what was supposed to be the biggest drug launch in history to a financial catastrophe. The resulting report is filled with fresh details about how one of the most storied biotech companies plotted with the federal agency that is supposed to regulate it, and how Biogen de

Documentation 98

Documentation FDA 98

The Checkup by Singlecare

DECEMBER 29, 2022

In the United States alone, more than 4 billion prescriptions are filled every month to treat various illnesses. Some of these medications carry a risk of rare but serious drug reactions that could land a person in the emergency room. Due to a lack of recognition and a paucity of communication between patients and healthcare providers, millions of reactions may go unreported every year.

Adverse Reactions 98

Adverse Reactions Chemotherapy Immunization Dosage 98

STAT

DECEMBER 29, 2022

For over two decades, a crisis of opioid overdoses has been one of the most urgent health care emergencies in the United States. Initially driven by the over-prescription of pharmaceutical opioids such as Oxycontin, a “second wave” of addiction deaths began as people transitioned from prescription opioids to heroin, a much riskier drug.

98

98

pharmaphorum

DECEMBER 29, 2022

A new Data Protection and Digital Information Bill is currently being considered by UK ministers. The Bill has been created to update and simplify the UK’s data protection framework with a view to reducing burdens on organisations, providing them with greater flexibility on how to comply with certain aspects of the data protection legislation and improving the clarity of the framework.

98

98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

DECEMBER 29, 2022

Pfizer said Thursday that its experimental gene therapy for hemophilia B significantly reduced the number of bleeds patients experienced over a year.  Data from the 45-patient trial could set the stage for a second gene therapy to be approved for patients with the rare and serious bleeding disorder in as many years. In November, UniQure won approval for Hemgenix, the first hemophilia B gene therapy.

98

98

Pharmacy Times

DECEMBER 29, 2022

Products include a vaccine for meningococcal disease and a new type of COVID-19 test.

Vaccines 131

Vaccines 131

STAT

DECEMBER 29, 2022

WASHINGTON — The Food and Drug Administration’s review and approval of a controversial Alzheimer’s drug was “rife with irregularities,” including dozens of undisclosed calls and emails with Biogen and an “inappropriate” level of coordination between the drugmaker and regulators, a congressional investigation concluded.

FDA 98

FDA 98

Drug Store News

DECEMBER 29, 2022

Drug Store News recently spoke with Dawn Garvey, chief financial officer, about the company’s anniversary, its future and where the greeting cards category is headed.

98

98

STAT

DECEMBER 29, 2022

Dear Reader, From STAT’s first investigations in June 2021 revealing why the FDA gave the go-ahead for a marginally effective Alzheimer’s drug manufactured by Biogen, we have relentlessly stayed on the story. We’ve reported on the disastrous financial and leadership consequences for a one-time biopharma behemoth, as well as the dashed hopes of millions of people with dementia who had heard of a new drug called Aduhelm.

FDA 98

FDA 98

Drug Store News

DECEMBER 29, 2022

Crossmark’s Kristen Abreu discusses how the company invests in technology and tools to help retail brands understand shopper trends.

98

98

Drug Topics

DECEMBER 29, 2022

Take a look back at our most popular dermatology coverage for 2022.

98

98

Pharmacy Times

DECEMBER 29, 2022

Both benefits and concerns exist, but implementing policies and regulations promotes employee productivity, guards safety.

123

123

Fierce Pharma

DECEMBER 29, 2022

After FDA's Ukoniq pull, TG Therapeutics wins commercial mulligan with Briumvi to enter crowded MS arena. fkansteiner. Thu, 12/29/2022 - 09:30.

FDA 84

FDA 84

The Guardian - Pharmaceutical Industry

DECEMBER 29, 2022

House of Representatives’ report details ‘corporate greed’ and ‘atypical review process’ preceding agency’s approval of Biogen’s drug US drug regulators failed to follow their own guidance and practices when they approved the controversial Alzheimer’s drug Aduhelm, a congressional report said on Thursday. The US food and drug administration’s (FDA) process of approval, it said, had been “rife with irregularities”, and the FDA’s interactions with maker Biogen had been “atypical”.

FDA 61

FDA 61

Fuld

DECEMBER 29, 2022

Social Media and Text Analytics. Leverage social media and NLP (natural language processing) analytics for applications in marketing and beyond. Marketing. Identifying key Influencers to maximize influence, creating customer social personas, social CRM, tracking and benchmarking competitor social media, and media performance analytics. Customer Voice.

52

52

BuzzRx

DECEMBER 29, 2022

Kidney stones and bladder stones are hard deposits of minerals and salts that form in the urinary tract. Other names for stones in the urinary tract include renal calculi, urolithiasis, and nephrolithiasis. Bladder stones & kidney stones develop in concentrated urine. When urine is concentrated, it causes the minerals in the urine to crystallize and form stones.

52

52

Fuld

DECEMBER 29, 2022

Competitive Intelligence Analytics. Track and stay ahead of your competition through automated KPI and news feeds visualized in dynamic dashboards. Company-specific data. Tracking financials, press releases, product launches, key developments, news mentions, employment trends, engagement trends from social media, and more. Industry-specific metrics.

52

52

BuzzRx

DECEMBER 29, 2022

If you’ve noticed blood in your urine , you’re probably worried about what it means. The medical term for this is hematuria. Blood in the urine can be from something harmless, like eating certain foods, but blood in your urine can also indicate something more far more serious, such as a urinary tract infection , kidney stones , kidney cancer, or bladder cancer.

Immunization 52

Immunization 52

The Checkup by Singlecare

DECEMBER 29, 2022

Is Nuedexta covered by insurance? | How much does Nuedexta cost without insurance? | How to get Nuedexta without insurance. Nuedexta is a brand-name prescription drug that treats pseudobulbar affect ( PBA). Consisting of involuntary and unexpected outbursts of crying or laughing unrelated to mood, PBA is a relatively common symptom of underlying neurological conditions, such as stroke, brain injury , dementia, multiple sclerosis , Parkinson’s disease, or amyotrophic lateral sclerosis (ALS).

Insurance 52

Insurance Insurance Coverage Labelling FDA 52

PQA

DECEMBER 29, 2022

PQA has published nearly 90 blogs this year, providing insights and updates on our work to improve medication use quality. As we close out 2022, here’s a look back at the top five blogs of the year. 5. PQA’s Plan to Improve Oral Anticancer Medication Use Quality (October 10) PQA is launching a national initiative to prioritize research and measurement strategies to improve the quality of care for individuals using oral anticancer medications (OAM).

Patient Care 52

Patient Care 52

The Checkup by Singlecare

DECEMBER 29, 2022

Is clopidogrel covered by insurance? | How much does clopidogrel cost without insurance? | How to get clopidogrel without insurance. Clopidogrel is a generic prescription blood thinner used to help reduce the risk of heart attack, stroke, or death in people with chest pain (angina), peripheral arterial disease, or for people who have recently had a heart attack or stroke.

Insurance 52

Insurance Insurance Coverage FDA 52

Pharmaceutical Technology

DECEMBER 29, 2022

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZeneca ’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers. The combination of Imfinzi and Imjudo has been approved to treat unresectable hepatocellular carcinoma (HCC) in adult patients. It has also been authorised to treat unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) along with chemotherapy.

Chemotherapy 52

Chemotherapy 52

The Checkup by Singlecare

DECEMBER 29, 2022

Compare omeprazole alternatives | Nexium | Prevacid | Pepcid | Carafate | Tums | Natural alternatives | How to switch meds. The brand-name heartburn medication Prilosec, known generically as omeprazole , has such widespread usage that it is a household name. This is partly related to the prevalence of gastroesophageal reflux disease (GERD) , but in addition, the drug’s impressive effectiveness has earned it this status.

Dosage 52

Dosage Compounding 52

pharmaphorum

DECEMBER 29, 2022

As we close out the year, pharmaphorum’s editorial team sat down together for a roundtable discussion of some of the biggest trends they tracked this year in the world of pharma. . Join editor-in-chief Jonah Comstock, founder Paul Tunnah, Deep Dive editor Eloise McLennan, and web editor Nicole Raleigh for a wide-ranging discussion touching on clinical trials, patient centricity, COVID-19’s impact on digital health, precision medicine, and artificial intelligence and machine learning. .

52

52